For more than 60 years, metformin has been the most prescribed drug for type 2 diabetes in the world. Cheap, reliable, and backed by decades of clinical evidence, it has been handed to hundreds of millions of people as the standard first-line treatment for managing blood sugar. Doctors knew it worked. What nobody fully understood, until now, was how.
In September 2025, researchers at Baylor College of Medicine published a study in Science Advances that changed the picture entirely. Metformin, it turns out, does not only act on the liver and the gut as long assumed. It works directly in the brain. The discovery has significant implications not just for how diabetes is treated, but for how care providers supporting people with type 2 diabetes think about the complexity of the condition and the people living with it.
What the Research Actually Found
The Baylor team, led by pathophysiologist Dr Makoto Fukuda, focused on a small protein called Rap1, found in a specific region of the brain known as the ventromedial hypothalamus, or VMH. The VMH is a critical control centre for whole-body glucose metabolism, regulating appetite, energy balance, and blood sugar levels. The researchers discovered that metformin’s ability to lower blood sugar at clinically relevant doses depends on suppressing Rap1 activity in this brain region.
To test this, they used genetically modified mice that lacked Rap1 in the VMH. Fed a high-fat diet to mimic type 2 diabetes, these mice showed no blood sugar reduction when given low doses of metformin, even though other diabetes medications including insulin continued to work normally. Then came the most striking finding of all: when researchers injected tiny amounts of metformin directly into the brains of diabetic mice, blood sugar fell significantly, even at doses thousands of times smaller than those typically given orally. The brain, it turns out, is far more sensitive to metformin than the liver or gut ever were.
Why This Matters Beyond the Laboratory
This is not an abstract scientific finding. It reframes what metformin actually is. It is not simply a blood sugar management tool that acts peripherally. It is a drug with a direct neurological mechanism, one that was operating quietly for six decades without anyone knowing it was there.
The clinical consequences of this discovery are still unfolding. In February 2026, NICE updated its guidance on type 2 diabetes management in adults, recommending that most people newly diagnosed should now be offered metformin alongside an SGLT-2 inhibitor from the start rather than metformin alone. The updated guidance could prevent around 17,000 deaths over three years across the UK. It also recommends slow-release metformin as standard, which is easier on the stomach and supports better treatment adherence.
Alongside the Baylor research, a 2025 study of more than 400 postmenopausal women found that those taking metformin had a 30 per cent lower risk of dying before the age of 90 compared with those on an alternative diabetes drug. Separate research has linked metformin to slowing brain aging, reducing wear and tear in the brain, and potentially lowering the risk of long COVID. The Baylor team now plans to investigate whether the same brain Rap1 signalling pathway is responsible for these additional effects.
Type 2 Diabetes and the Social Care Caseload
Type 2 diabetes is one of the most prevalent long-term conditions in the populations that health and social care providers serve. Approximately 4.3 million people in the UK have type 2 diabetes. Older adults, people in deprived communities, people with learning disabilities, and people in supported living or residential settings are all significantly overrepresented in diabetes prevalence data. For many of these individuals, diabetes is not a standalone condition. It co-exists with cardiovascular disease, chronic kidney disease, obesity, dementia, and mobility limitations. The interactions between these conditions create exactly the kind of care complexity that commissioners expect providers to understand and evidence in tender submissions.
For providers delivering domiciliary care to people living at home with type 2 diabetes, the implications of the NICE 2026 guidance are direct. Medication regimes are changing. More people will be started on combination therapy. Providers supporting medication adherence need staff who understand why a person is taking two diabetes medications rather than one, what each does differently, and what side effects to monitor. That level of clinical awareness is no longer aspirational. It is what commissioners expect to see evidenced in workforce training records and method statements.
What the Metformin Brain Discovery Means for Dementia and Cognitive Care
Perhaps the most significant long-term implication of the Baylor discovery for health and social care is the growing body of evidence linking metformin to brain health. Research has already suggested the drug may slow brain aging. The discovery of a direct hypothalamic mechanism opens the possibility that metformin’s neurological effects are not coincidental but structural, built into the drug’s core mechanism of action.
For providers delivering nursing care and residential care to people with both type 2 diabetes and cognitive decline, this creates new clinical questions. How does a person’s diabetes management interact with their cognitive trajectory? How are medication reviews structured for people who cannot reliably report side effects? How does the care team support glucose monitoring and medication adherence for someone with moderate dementia? These are not theoretical questions. They are the operational realities that CQC inspectors and commissioning managers will probe in quality assessments.
What This Means for Providers Bidding for Diabetes-Related Contracts
The NICE 2026 guidance update, the Baylor brain discovery, and the broader shift in understanding of what metformin does all point in the same direction. Diabetes care is becoming more sophisticated, more neurologically aware, and more demanding of clinical competence from the providers commissioned to support people living with it.
Providers bidding for reablement services for people discharged from hospital following diabetic complications, or for domiciliary care frameworks that include people with complex long-term conditions, will be assessed on whether their workforce training, care planning processes, and clinical oversight structures are genuinely fit for the updated evidence base. Generic chronic condition management policies will not score well against these criteria. Specific, evidenced, and up to date responses will.
Commissioners are increasingly looking for providers who read the evidence, understand it, and can demonstrate that their care model reflects it. The metformin brain story is exactly the kind of development that separates providers who are paying attention from those who are not.
AssuredBID
Type 2 diabetes is one of the most complex and prevalent conditions in the social care caseload, and the evidence base around how to support people living with it is moving quickly. Our bid management services help you translate clinical awareness into written evidence that commissioners can score, from method statements to workforce governance frameworks.
Book a free consultation at assuredbid.co.uk/book-a-consultation
